Tag - CRVO

Developments

CervoMed completes enrollment for study of neflamapimod in nfvPPA

CervoMed (NASDAQ: CRVO) has announced that it has completed enrollment in the Phase 2a study to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in patients with nonfluent/agrammatic variant...

July 9, 2026

Developments

CervoMed reports new data from trial showing potential of neflamapimod for DLB

CervoMed (NASDAQ: CRVO) has announced additional data from its Phase 2b RewinD-LB trial, demonstrating neflamapimod’s potential as a treatment for dementia with Lewy bodies (DLB). According to CervoMed, FDA feedback on...

October 8, 2025

Developments

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

CervoMed (NASDAQ:CRVO) announced that the FDA has granted orphan drug designation (ODD) to its lead investigational therapy, neflamapimod, for the treatment of frontotemporal dementia (FTD). Following the announcement...

November 28, 2024

Tag - CRVO

CervoMed completes enrollment for study of neflamapimod in nfvPPA

CervoMed reports new data from trial showing potential of neflamapimod for DLB

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

Subscribe